PharmDr. Hana Bavlovič Piskáčková, Ph.D.

Present position

Contact information

  • Tel. +420 495 067 309
  • Email: piskacha@faf.cuni.cz
  • ORCID ID:  0000-0002-9817-7247
  • Scopus Author ID: 57207578195

Research interests

  • Separation technique – HPLC
  • Sample preparation prior LC-MS analysis of drugs – conventional extraction techniques and electromembrane extraction
  • Development of LC-MS methods for targeted assay of novel drugs and the metabolites in biological materials, stability of drugs/drug candidates in biological environments

Education and professional carrier

Teaching experience

  • Teaching of Pharmaceutical Analysis I. and Pharmaceutical Analysis II., Analysis of Exogenous Compounds in Biological Material, Bioanalysis of Drugs
  • Supervisor of 2 M.Sc. theses

Grants received

Principal investigator:

  • 2017-2019 Grant Agency of Charles University: Utilization of UHPLC-MS/MS for study of new cardioprotectives in cardiac cells and organism (GAUK No. 1550217)

Member of the research team:

  • 2021-2023 Grant Agency of Academy of Science of Czech Republic: Využití chemické biologie pro studium antracyklinové kardiotoxicity a farmakologické kardioprotekce se zaměřením na topoisomerasu II beta (GAČR No. 21-16195S)
  • 2018-2020 Grant Agency of Academy of Science of Czech Republic: Studium jednotlivých isoforem topoisomerasy II v protinádorovém a kardiotoxickém působení
  • antracyklinů a jejich modulací bisdioxopiperaziny (GAČR No. 18-08169S)
  • 2017 Grant Agency of Charles University: Comprehensive analytical and bioanalytical study of sobuzoxane – a new anti-cancer drug (GAUK No. 344615)

Stays

  • 2019-2020 Erasmus+, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway, Supervisor: prof. Stig Pedersen-Bjergaard (5 months)
  • 2015-2016 Erasmus+, Faculty of Pharmacy, University of Porto, Portugal, Supervisor: Prof. Jorge MA Oliveira Ph.D. (4 months)

Cooperation

Faculty of Pharmacy in Hradec Kralove, Charles University in Prague

  • Prof. PharmDr. Tomáš Šimůnek, Ph.D. -  In vitro investigation of bioactivation of cardioprotective agents
  • Assoc.PharmDr. Jaroslav Roh, Ph.D., Assoc. – Chemical synthesis of metabolites

Faculty of Medicine in Hradec Kralove, Charles University in Prague

  • Assoc. Prof. PharmDr. Martin Štěrba, Ph.D. - Pharmacokinetics and bioactivation of cardioprotective agents

University of Oslo, Norway

  • Prof. Stig Pedersen-Bjergaard -  Electromembrane extraction

Publication

Author and co-author of 9 articles in international journals with IF; 47 citations (WoS; excluding self-citations); H-index: 5 (WoS). The links to full texts are available at the Pharmaceutical Analysis Group website.

  • Bavlovič Piskáčková H, Nemeškalová A, Sýkora D, Kučera R, Pedersen-Bjergaard, S, Najmanová V, Štěrbová-Kovaříková P, Kuchař M. Advanced microextraction techniques for the analysis of amphetamines in human breast milk and their comparison with conventional methods. JPBA (2022) 
  • Bavlovič Piskáčková H, Kollárová-Brázdová P, Kučera R, Macháček M, Pedersen-Bjergaard S, Štěrbová-Kovaříková P, The electromembrane extraction of pharmaceutical compounds from animal tissues. Anal. Chim. Acta 1177 (2021)
  • Bavlovič Piskáčková H, Øiestad EL, Váňová N, Lengvarská J, Štěrbová-Kovaříková P, Pedersen-Bjergaard S. Electromembrane extraction of anthracyclines from plasma: Comparison with conventional extraction techniques. Talanta. 223: 121748 (2021)
  • Bavlovič Piskáčková H, Jansová H, Kubeš J, Karabanovich G, Váňová N, Kollárová-Brázdová P, Melnikova J, Jirkovská A, Lenčová-Popelová O, Chládek J, Roh J, Šimůnek T, Štěrba M, Štěrbová-Kovaříková P. Development of water-soluble pro-drugs of bisdioxopiperazine topoisomerase IIβ inhibitor ICRF 193 as potential cardioprotective agents against anthracycline cardiotoxicity. Sci Rep. 11: 4456 (2021)
  • Jirkovský E., Jirkovská A., Bavlovič Piskáčková H., Skalická V., Pokorná Z., Karabanovich G., Brázdová P., Kubeš J., Lenčová-Popelová O., Mazurová Y., Adamcová M., Lyon A.R., Roh J., Šimůnek T., Štěrbová-Kovaříková P., Štěrba M. Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase IIβ and not metal chelation. Circ Heart Fail (2021)
  • Jirkovská A., Karabanovich G., Kubeš J., Skalická V., Melnikova I., Korábečný J., Kučera T., Jirkovský E., Nováková L., Bavlovič Piskáčková H., Škoda J., Štěrba M., Austin C.A., Šimůnek T., Roh J. Structure-activity relationship study of dexrazoxane analogues reveals ICRF-193 as the most potent bisdioxopiperazine against anthracycline toxicity to cardiomyocytes due to its strong topoisomerase IIβ interactions. J. Med. Chem. 64(7): 3997-4019 (2021)
  • Kollárová-Brázdová P, Jirkovská A, Karabanovich G, Pokorná Z, Roh J, Jirkovský E, Bavlovič Piskáčková H, Reimerová P, Mazurová Y, Adamcová M, Skalická V, Štěrbová-Kovaříková P, Šimůnek T and Štěrba M. Investigation of structure-activity relationships of dexrazoxane analogs reveals topoisomerase IIβ interaction as a prerequisite for effective protection against anthracycline cardiotoxicity. J. Pharmacol. Exp. Ther. 373(3):402-415 (2020)
  • Reimerová P, Jirkovská A, Bavlovič Piskáčková H, Karabanovich G, Roh J, Šimůnek T, Štěrbová-Kovaříková P. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. Sci Rep 9:4524 (2019)
  • Reimerová P, Stariat J, Bavlovič Piskáčková H, Jansová H, Roh J, Kalinowski DS, Macháček M, Šimůnek T, Richardson DR, Štěrbová-Kovaříková P. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Anal Bioanal Chem 411:2383–2394 (2019)

© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 03 Hradec Králové, Czech Republic
Website information | Powered by Kentico